



DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors

Dottikon, Switzerland, July 6, 2012 – For the business year 2011/12, the shareholders approved all proposals of the Board of Directors at the 7th Annual General Meeting of DOTTIKON ES HOLDING AG in Baden. 99 present shareholders represented 1'162'039 voting rights and therefore 95.9% of the total of 1'212'155 registered shares with voting rights.


The Annual Report, financial statements 2011/12, and the consolidated financial statements 2011/12 of DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. Further the dividend payment of CHF 4.00 per registered share entitled to dividends was accepted. Discharge for the business year 2011/12 was granted to the responsible Board of Directors and Management. Members of the Board Dr. Markus Blocher and Dr. Alfred Scheidegger are reelected, and Dr. Thomas Früh newly appointed to the Board, all for a term of one year. Statutory auditor for an additional term of one year is KPMG AG, Zurich.

The dividend will be paid out to all shareholders entitled to dividends on Friday, July 13, 2012. Shares of DOTTIKON ES HOLDING AG will be traded ex dividend from Tuesday, July 10, 2012.

After the Annual General Meeting, the Board of Directors newly constituted itself and elected Dr. Markus Blocher as Chairman as well as Dr. Thomas Früh as Deputy Chairman of the Board of Directors.

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), is specialized in hazardous chemical reactions. Its safety culture created over the last 100 years is utilized to innovatively use hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing, to question, tighten or shorten conventional chemical synthesis routes, improve yields, selectivity, and purity, as well as to reduce waste.

DOTTIKON ES employs its versatile technology and equipment portfolio to design, develop, and continuously improve chemical processes, scale up from kilograms to multi-tons, as well as to manufacture high-quality intermediates and exclusive active pharmaceutical ingredients (APIs) for the world's leading pharmaceutical and chemical companies. The one-site strategy of DOTTIKON ES allows short decision and communication pathways. This ensures quick and efficient project development as well as clear and transparent communication with the customers.



dottikon

DOTTIKON ES HOLDING AG is listed at the SIX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Markus Blocher, Ph.D.

CEO

Dottikon ES Holding AG

Tel +41 56 616 82 01

Fax +41 56 616 89 45

investor-relations@dottikon.com